Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings

IOVA·Reported May 8, 2025·After market close

Iovance Biotherapeutics, Inc. reported Q1 2025 revenue of $49.3M (+6798.5% YoY), missed analyst consensus of $82.4M by $33.1M. Diluted EPS came in at $-0.36 (+14.3% YoY), missed the $-0.25 consensus by $0.11.

Revenue
$49.3Mmissed by $33.1M
Consensus: $82.4M
Diluted EPS
$-0.36missed by $0.11
Consensus: $-0.25
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001558370-25-007009

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Iovance Biotherapeutics, Inc.'s Q1 2025 earnings report.

Iovance Biotherapeutics, Inc. (IOVA) reported Q1 2025 earnings on May 8, 2025 after market close.

Iovance Biotherapeutics, Inc. reported revenue of $49.3M and diluted EPS of $-0.36 for Q1 2025.

Revenue missed the consensus estimate of $82.4M by $33.1M. EPS missed the consensus estimate of $-0.25 by $0.11.

Compared to the same quarter a year prior, revenue grew 6798.5% from $715.0K a year earlier and diluted EPS grew 14.3% from $-0.42.

You can read the 10-Q periodic report (0001558370-25-007009) directly on SEC EDGAR. The filing index links above go to sec.gov.